Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694
Yiming Zhong, Shuai Dong, Ethan Strattan, et al.
Journal of Biological Chemistry (2015) Vol. 290, Iss. 10, pp. 5960-5978
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
Kodappully Sivaraman Siveen, Kirti S. Prabhu, Iman W. Achkar, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 100
Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
Marian C. Bryan, Naomi S. Rajapaksa
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 20, pp. 9030-9058
Closed Access | Times Cited: 69
Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome
Suman Rao, Deepak Gurbani, Guangyan Du, et al.
Cell chemical biology (2019) Vol. 26, Iss. 6, pp. 818-829.e9
Open Access | Times Cited: 52
Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis
Kristina Lechner, Markus F. Neurath, Benno Weigmann
Journal of Molecular Medicine (2020) Vol. 98, Iss. 10, pp. 1385-1395
Open Access | Times Cited: 48
Advances and Perspectives in the Treatment of T-PLL
Till Braun, Jana von Jan, Linus Wahnschaffe, et al.
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 2, pp. 113-124
Open Access | Times Cited: 42
Hierarchy of signaling thresholds downstream of the T cell receptor and the Tec kinase ITK
Michael P. Gallagher, James Conley, Pranitha Vangala, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 35
Open Access | Times Cited: 40
Conditional requirement for dimerization of the membrane-binding module for BTK signaling in lymphocyte cell lines
Timothy J. Eisen, Sam Ghaffari-Kashani, Chien‐Lun Hung, et al.
Science Signaling (2025) Vol. 18, Iss. 869
Closed Access
Covalent binders in drug discovery
Anil Vasudevan, M.A. Argiriadi, Aleksandra Baranczak, et al.
Progress in medicinal chemistry (2019), pp. 1-62
Closed Access | Times Cited: 39
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia
Charles Herbaux, Christoph Kornauth, Stéphanie Poulain, et al.
Blood (2021) Vol. 137, Iss. 25, pp. 3495-3506
Open Access | Times Cited: 28
Activation of the Tec Kinase ITK Controls Graded IRF4 Expression in Response to Variations in TCR Signal Strength
James Conley, Michael P. Gallagher, Anjana Rao, et al.
The Journal of Immunology (2020) Vol. 205, Iss. 2, pp. 335-345
Open Access | Times Cited: 28
A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression
Hyoung‐Soo Cho, Hyun Mu Shin, Helena Haberstock-Debic, et al.
The Journal of Immunology (2015) Vol. 195, Iss. 10, pp. 4822-4831
Open Access | Times Cited: 33
Multidomain Control Over TEC Kinase Activation State Tunes the T Cell Response
Amy H. Andreotti, R Joseph, James Conley, et al.
Annual Review of Immunology (2018) Vol. 36, Iss. 1, pp. 549-578
Open Access | Times Cited: 31
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma
Yalu Liu, Xiaogan Wang, Lijuan Deng, et al.
Cancer Cell International (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 26
Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors
Jiamin Zheng, Jun Wu, Xiao Ding, et al.
Bioorganic & Medicinal Chemistry Letters (2021) Vol. 38, pp. 127862-127862
Closed Access | Times Cited: 21
Differential T ‐cell receptor signals for T helper cell programming
Penelope A. Morel
Immunology (2018) Vol. 155, Iss. 1, pp. 63-71
Open Access | Times Cited: 25
Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase
Christopher M. Harris, Sage E. Foley, Eric R. Goedken, et al.
SLAS DISCOVERY (2018) Vol. 23, Iss. 10, pp. 1040-1050
Open Access | Times Cited: 24
The Tec kinase ITK is essential for ILC2 survival and epithelial integrity in the intestine
Hyoung‐Soo Cho, Andrea Reboldi, Jason A. Hall, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 23
Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications
Sabrina Solouki, Avery August, Weishan Huang
Pharmacology & Therapeutics (2019) Vol. 201, pp. 39-50
Open Access | Times Cited: 23
Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality
Adrien Krug, Gamze Tari, Aymen Saidane, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2392-2392
Open Access | Times Cited: 13
T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment
Marc Gutierrez, Patrick Bladek, Busra Bacik Goksu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12106-12106
Open Access | Times Cited: 7
Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances
Mohammad Hojjat‐Farsangi
Journal of drug targeting (2015) Vol. 24, Iss. 3, pp. 192-211
Open Access | Times Cited: 18
Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
Justin F. Creeden, Khaled Alganem, Ali Sajid Imami, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8823-8823
Open Access | Times Cited: 17
ITK and RLK Inhibitor PRN694 Improves Skin Disease in Two Mouse Models of Psoriasis
Jessica Fuhriman, M.C.G. Winge, Helena Haberstock-Debic, et al.
Journal of Investigative Dermatology (2017) Vol. 138, Iss. 4, pp. 864-871
Open Access | Times Cited: 17
A negative role for the interleukin-2-inducible T-cell kinase (ITK) in human Foxp3+ TREG differentiation
Polina Mamontov, Ryan Eberwine, Jackie Perrigoue, et al.
PLoS ONE (2019) Vol. 14, Iss. 4, pp. e0215963-e0215963
Open Access | Times Cited: 16
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL)
Sabine Dondorf, Alexandra Schrader, Marco Herling
Journal of Biological Chemistry (2015) Vol. 290, Iss. 16, pp. 10568-10569
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top